ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.46
+3.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2M | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 1.2M | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 12.4M | 10.4M | 7.2M | 7.6M | 19.8M |
| SG&A Expense | 4.8M | 4.9M | 4.7M | 5.4M | 6.9M |
| General & Admin Expense | 4.8M | 4.9M | 4.7M | 5.4M | 6.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (3.3M) | (5.1M) | (5.2M) | (2.2M) | (2.5M) |
| Total Operating Expenses | 13.8M | 10.2M | 6.7M | 10.7M | 24.2M |
| Cost and Expenses | 13.8M | 10.2M | 6.7M | 10.7M | 24.2M |
| Operating Income (EBIT) | (12.7M) | (10.2M) | (6.7M) | (10.7M) | (24.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 1.2M |
| Interest Expense | 16.0K | 18.8K | 1.3M | 353.9K | 109.5K |
| Net Interest Income | (16.0K) | (18.8K) | (1.3M) | (354.0K) | 1.1M |
| Other Non-Op Income/Expense | 37.2K | 64.8K | (1.3M) | 91.9K | 14.4K |
| Non-Operating Income (excl Interest) | (41.5K) | (83.5K) | (33.6K) | (445.9K) | (123.9K) |
| EBT (Pre-Tax Income) | (12.6M) | (10.2M) | (8.0M) | (10.6M) | (24.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.6M) | (10.2M) | (8.0M) | (10.6M) | (24.2M) |
| Earnings from Cont. Ops | (12.6M) | (10.2M) | (8.0M) | (10.6M) | (24.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.6M) | (10.2M) | (8.0M) | (10.6M) | (25.1M) |
| Per Share | |||||
| Basic EPS | ($2.76) | ($3.98) | ($4.57) | ($4.69) | ($139.44) |
| Diluted EPS | ($2.52) | ($3.98) | ($4.57) | ($4.69) | ($139.44) |
| Revenue Per Share | $0.09 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 13.0M | 2.6M | 1.7M | 2.3M | 179932 |
| Diluted Shares Outstanding | 13.0M | 25.6M | 1.7M | 2.3M | 179932 |
| Profitability Metrics | |||||
| EBITDA | (12.6M) | (10.2M) | (6.7M) | (10.3M) | (24.1M) |
| D&A | 6.5K | 6.5K | — | — | — |
| EBIT | (12.6M) | (10.2M) | (6.7M) | (10.3M) | (24.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026